Georgopoulos D, Wong D, Anthonisen N R
Department of Medicine, University of Manitoba, Winnipeg, Canada.
Chest. 1990 Feb;97(2):280-4. doi: 10.1378/chest.97.2.280.
Eleven patients with severe COPD were examined to determine whether tolerance to beta 2-agonists developed after long-term inhalation therapy with these agents. Before the study all patients were on regular treatment with inhaled salbutamol for six months. At the beginning of the study, response of FEV1 to inhaled salbutamol was measured. Dose-response curves were measured after three weeks of treatment with ipratropium bromide and again after a three-week course of inhaled salbutamol. After ipratropium bromide treatment, responses to low doses of salbutamol tended to be larger than after salbutamol treatment, but differences were not significant. Three hours after the last inhalation of salbutamol the FEV1 was lower on days 1 and 42 than on day 21. We conclude that long-term inhalation therapy with beta 2-agonists in patients with COPD decreases the duration of the bronchodilation produced by the same agents but does not affect the peak response.
对11名重度慢性阻塞性肺疾病（COPD）患者进行了检查，以确定长期吸入β2-受体激动剂治疗后是否会产生耐受性。研究前，所有患者均接受吸入沙丁胺醇常规治疗六个月。研究开始时，测量了第一秒用力呼气容积（FEV1）对吸入沙丁胺醇的反应。在使用异丙托溴铵治疗三周后以及吸入沙丁胺醇三周疗程后再次测量剂量反应曲线。异丙托溴铵治疗后，对低剂量沙丁胺醇的反应往往比沙丁胺醇治疗后更大，但差异不显著。在最后一次吸入沙丁胺醇三小时后，第1天和第42天的FEV1低于第21天。我们得出结论，COPD患者长期吸入β2-受体激动剂治疗会缩短相同药物产生的支气管扩张持续时间，但不影响峰值反应。
